Member Info for JBTs

Total embarrassment to the company and Oberon Capital.

Agreed. Excellent appointment for the company. Can only be onwards and upwards now!

More good news with this update. This stock looks cheap to me!

Excellent RNS....very positive update.

Canny buyers this morning as it feels like there is an update on the horizon as the company have always said it was their intension to keep the market aware of developments.

Further good news with "out with the old and in with the new" strategy occurring at Grant Polymer. Not only is it a cost saving it is clear evidence of the strategy being undertaken by the new board to utterly transform this business and I look forward to further new appointments in due course to assist this process. Very good news in my opinion and I look forward to further updates and can only reiterate by opinion above!

Don't worry about it let them take their grubby little turns and stick with this longer term where the proper money will be made!

Excellent post...very informative. Very bullish with these new appointments for this company.

Further evidence this morning of "out with old and in with the new!" Not only does this show the departure of the dead wood from previous debacles but that the new fantastic team are driving things forward their way. Also saves a totally unnecessary cost to the business. Jolly good news for shareholders.

Professor David Nutt: Global Leading Expert in Neuropsychopharmacology

Key Roles: Professor at Imperial College London; former President of the European Brain Council, European College of Neuropsychopharmacology, British Neuroscience Association, and British Association of Psychopharmacology.

Groundbreaking Research: Led a pivotal study ranking drugs by their relative harms, highlighting the discrepancies in drug policy. His research on psychedelics, published in top journals like The Lancet and New England Journal of Medicine, has advanced the understanding of their potential therapeutic benefits.

Policy Influence: As Chair of the UK Advisory Council on the Misuse of Drugs, he famously published a report showing alcohol to be more harmful than many illegal drugs, sparking widespread debate and policy reconsideration.

Leadership and Publications: Author of over 400 scientific papers and several influential books, including "Drugs Without the Hot Air." His work is highly cited, with an h-index exceeding 100, reflecting his substantial impact on the field.

Innovative Treatments: Pioneering the clinical use of psychedelics for conditions like depression and PTSD, supported by successful trials and featured in leading media outlets. His recent studies on psilocybin therapy were pivotal in reviving interest in psychedelic research for mental health.

Fantastic news for shareholders.

This interview now just out on Proactive Investors Live is a must read for any (or potential) shareholder. Very bullish and makes these things look extremely cheap.

Just heard that there is an interview with Proactive Investors and the GPL CEO at 10.00am which should be well worth listening to.

Prof David Nutt, CSO Awakn Life Sciences Corp, commented:

"This Collaboration is a significant step forward for our new chemical entity programme. Graft Polymer's expertise in drug delivery systems will be invaluable as we advance our research.

"We are confident that this partnership will accelerate the development of new therapeutic options for addiction and mental health, areas in desperate need of innovative solutions." David John Nutt is an English neuropsychopharmacologist specialising in the research of drugs that affect the brain and conditions such as addiction, anxiety, and sleep. He is the chairman of Drug Science, a non-profit which he founded in 2010 to provide independent, evidence-based information on drugs.

David John Nutt is an English neuropsychopharmacologist specialising in the research of drugs that affect the brain and conditions such as addiction, anxiety, and sleep. He is the chairman of Drug Science, a non-profit which he founded in 2010 to provide independent, evidence-based information on drugs.

These guys know their market...very bullish with this RNS.

Or above!

Davey. I have never read so much rubbish from a very jealous person that has obviously missed out on this marvellous tiddler. With hinted news to come from the excellent new CEO you really have let this one slip old boy. Never mind you may have time in the morning to join the party before they move again.

Such a sceptic!

I say strong buy but obviously when they return...think this could be the tiddler of the year!!!!

Think I may have stumbled across an extremely interesting minnow here. Following the RNS put out this morning announcing the appointment of Anthony Tennyson as the new CEO there could be very exciting times ahead. His CV looks exceptional and has also a background in finance having worked at Merrill Lynch and Bank of Ireland both blue chip names. Besides that his career has been in Life Sciences and this is exactly what this company needs. With such a tiny market cap there is huge potential upside here.

I have to say the ridiculous delay in the "so called promised events" have resulted in the deterioration of the share price. Along with the Jennings exit (who has dealt quite well for himself as usual!) has resulted in an utter debacle for shareholders. I have never been so disappointed with the "promised land" in my 30 year City career. They are a disgrace to the AIM market!

I believe Optibiotix have also launched products with Costco Australia. These are examples of Optipharms OptiSlim premium range of shakes on Costco shelves in Australia and NZ. See Optislim Premium Shake For Her 1.68kg | Costco Australia, and Optislim Optiman Premium Shake For Him 1.68kg | Costco Au... They contain OptiBiome, which is SlimBiome by a unique name for Optipharm (OPTI own the trademark). Costco Aus/NZ is a $5bn business and as of 2023 Costco is the 3rd biggest retailer in the world with annual revenues of $242bn 😊. If this works well in Australia/NZ they will be taken across the world.

I believe Optibiotix have also launched products with Costco Australia. These are examples of Optipharms OptiSlim premium range of shakes on Costco shelves in Australia and NZ. See Optislim Premium Shake For Her 1.68kg | Costco Australia, and Optislim Optiman Premium Shake For Him 1.68kg | Costco Au... They contain OptiBiome, which is SlimBiome by a unique name for Optipharm (OPTI own the trademark). Costco Aus/NZ is a $5bn business and as of 2023 Costco is the 3rd biggest retailer in the world with annual revenues of $242bn 😊. If this works well in Australia/NZ they will be taken across the world.